NATCAPSUQ logo

Natural Capsules Limited

NATCAPSUQ·NSE·
₹159.50▲ +2.60 (+1.66%)
Market Cap167.10 Cr
PE Ratio-8.00
Volume1,572
Day High - Low160.50 - 158.00
52W High-Low234.00 - 136.36

Natural Capsules Limited (NATCAPSUQ): company summary

The company's business has deteriorated, with annual net profit swinging from a profit of ₹1 crore to a loss of ₹25 crore.

Natural Capsules Limited (NATCAPSUQ) is a micro-cap Healthcare company valued at ₹167 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move
Natural Capsules Limited last traded at ₹159.5, modestly up 1.66% on the day.
Recent developments
2026-06-30: The company reported a net loss of ₹25 crore for the fiscal year ended March 2026, marking a swing from a net profit of ₹1 crore in the previous year. 2026-06-30: The company's latest quarter ended with a net loss of ₹6 crore, matching the previous year's loss but showing a revenue increase of 7.8% to ₹49 crore.
Financial performance
The company's business has deteriorated, with annual net profit swinging from a profit of ₹1 crore to a loss of ₹25 crore. Revenue grew 10.8% year-on-year, but net profit margin collapsed to -13.2% from 0.6%, and return on equity turned negative at -7.7%. The latest quarter showed a loss of ₹6 crore, widening from the previous year's loss of ₹6 crore, while revenue rose 7.8% compared to the same quarter a year earlier.
Valuation multiples
A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 1.14 times book value.
Things to watch
The company is currently in a net loss, with a net profit margin of -13.2% and return on equity of -7.7%. The stock is 38.2% below its 52-week high, and the net profit has swung from a profit of ₹18 crore to a loss of ₹25 crore over the past three years.
Where it stands
Natural Capsules Limited ended its latest fiscal year with a net loss of ₹25 crore, a sharp decline from a net profit of ₹1 crore in the previous year. The stock is 38.2% below its 52-week high, and the company's net profit margin has collapsed to -13.2%. The latest quarter saw a loss of ₹6 crore, with revenue rising 7.8% year-on-year.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score
4.4/10
Weak
Fair Value
Sign in to see
ROE
-7.70%
Weak
P/E
-8.00x
Loss-making
Debt / Equity
0.52
Moderate
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed

Price performance

Day₹158.00
₹160.50
52W₹136.36
₹234.00
DocStoX take

Supported by growth (7.8) and valuation (6.0), but held back by momentum (1.2). Growth looks strong at 7.8, but that is offset by momentum at 1.2 and quality at 2.7. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence
4.4
/10
Weak
Quality
Weak
ROE -7.7%
Valuation
Fair
P/B 1.1× on assets (no earnings to value)
Growth
Strong
Revenue +18.5% 5Y CAGR
Risk
Elevated
D/E 0.52
Momentum
Weak
24% of 52-week range

At a glance

Market Cap
₹167 Cr
52W High / Low
₹234 / ₹136
Dividend Yield
0.52%
Promoter Holding
50.92%
EPS (TTM)
₹-16.44
Book Value
₹213.39

Key highlights

  • Revenue compounding 19% a year
  • Profit compounding 16% a year
  • Loss-making — no meaningful P/E
  • Momentum is weak (1.2/10)
2 Positives4 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Natural Capsules Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Natural Capsules Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited

Compare Natural Capsules Limited with peers

Natural Capsules Limited vs Sun Pharmaceutical Industries LimitedNatural Capsules Limited vs Divi's Laboratories LimitedNatural Capsules Limited vs Torrent Pharmaceuticals LimitedNatural Capsules Limited vs Apollo Hospitals Enterprise LimitedNatural Capsules Limited vs Zydus Lifesciences LimitedNatural Capsules Limited vs Laurus Labs Limited

Related tools & concepts

Value Natural Capsules Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing

Explore further

NATCAPSUQ newsLatest coverage & filingsOpen screenerFilter the whole market